Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 4.38 Billion USD | 2.46% |
| 2023 | 4.27 Billion USD | -11.43% |
| 2022 | 4.82 Billion USD | 20.76% |
| 2021 | 3.99 Billion USD | 29.21% |
| 2020 | 3.09 Billion USD | 22.89% |
| 2019 | 2.51 Billion USD | 2.22% |
| 2018 | 2.46 Billion USD | 18.7% |
| 2017 | 2.07 Billion USD | 12.3% |
| 2016 | 1.84 Billion USD | 0.94% |
| 2015 | 1.83 Billion USD | 0.17% |
| 2014 | 1.82 Billion USD | 1.52% |
| 2013 | 1.8 Billion USD | 6.22% |
| 2012 | 1.69 Billion USD | 10.64% |
| 2011 | 1.53 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.02 Billion USD | 4.28% |
| 2024 FY | 4.38 Billion USD | 2.46% |
| 2024 Q3 | 1.07 Billion USD | 4.88% |
| 2024 Q4 | 1.3 Billion USD | 21.14% |
| 2024 Q1 | 982 Million USD | -8.05% |
| 2023 Q4 | 1.06 Billion USD | 2.99% |
| 2023 Q3 | 1.03 Billion USD | -9.75% |
| 2023 Q2 | 1.14 Billion USD | 12.43% |
| 2023 FY | 4.27 Billion USD | -11.43% |
| 2023 Q1 | 1.02 Billion USD | -22.16% |
| 2022 Q3 | 1.27 Billion USD | 4.6% |
| 2022 FY | 4.82 Billion USD | 20.76% |
| 2022 Q1 | 1.02 Billion USD | -13.72% |
| 2022 Q4 | 1.31 Billion USD | 3.14% |
| 2022 Q2 | 1.21 Billion USD | 18.73% |
| 2021 Q4 | 1.18 Billion USD | 12.79% |
| 2021 FY | 3.99 Billion USD | 29.21% |
| 2021 Q3 | 1.05 Billion USD | 15.65% |
| 2021 Q1 | 845.7 Million USD | -10.75% |
| 2021 Q2 | 910.8 Million USD | 7.7% |
| 2020 FY | 3.09 Billion USD | 22.89% |
| 2020 Q3 | 760.6 Million USD | 5.43% |
| 2020 Q2 | 721.4 Million USD | 8.53% |
| 2020 Q4 | 947.6 Million USD | 24.59% |
| 2020 Q1 | 664.7 Million USD | -8.41% |
| 2019 FY | 2.51 Billion USD | 2.22% |
| 2019 Q1 | 551.8 Million USD | -19.48% |
| 2019 Q2 | 623 Million USD | 12.9% |
| 2019 Q3 | 617.5 Million USD | -0.88% |
| 2019 Q4 | 725.7 Million USD | 17.52% |
| 2018 Q1 | 543.9 Million USD | -11.83% |
| 2018 Q4 | 685.3 Million USD | 9.14% |
| 2018 Q3 | 627.9 Million USD | 3.56% |
| 2018 Q2 | 606.3 Million USD | 11.47% |
| 2018 FY | 2.46 Billion USD | 18.7% |
| 2017 Q2 | 483.7 Million USD | 9.38% |
| 2017 Q3 | 532.6 Million USD | 10.11% |
| 2017 Q4 | 616.9 Million USD | 15.83% |
| 2017 FY | 2.07 Billion USD | 12.3% |
| 2017 Q1 | 442.2 Million USD | -16.91% |
| 2016 FY | 1.84 Billion USD | 0.94% |
| 2016 Q2 | 454.9 Million USD | 7.54% |
| 2016 Q4 | 532.2 Million USD | 21.51% |
| 2016 Q1 | 423 Million USD | -17.08% |
| 2016 Q3 | 438 Million USD | -3.72% |
| 2015 FY | 1.83 Billion USD | 0.17% |
| 2015 Q4 | 510.1 Million USD | 14.22% |
| 2015 Q1 | 418.3 Million USD | -19.5% |
| 2015 Q3 | 446.6 Million USD | -2.02% |
| 2015 Q2 | 455.8 Million USD | 8.96% |
| 2014 Q2 | 440.7 Million USD | 6.37% |
| 2014 FY | 1.82 Billion USD | 1.52% |
| 2014 Q3 | 453.1 Million USD | 2.81% |
| 2014 Q1 | 414.3 Million USD | -17.99% |
| 2014 Q4 | 519.6 Million USD | 14.68% |
| 2013 Q3 | 447 Million USD | 2.5% |
| 2013 Q4 | 505.2 Million USD | 13.02% |
| 2013 FY | 1.8 Billion USD | 6.22% |
| 2013 Q1 | 412 Million USD | 0.0% |
| 2013 Q2 | 436.1 Million USD | 5.85% |
| 2012 FY | 1.69 Billion USD | 10.64% |
| 2011 FY | 1.53 Billion USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.39 Billion USD | -83.029% |
| Bausch Health Companies Inc. | 8.75 Billion USD | 49.971% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -317.516% |
| Elanco Animal Health Incorporated | 4.41 Billion USD | 0.815% |
| Perrigo Company plc | 4.65 Billion USD | 5.898% |
| Teva Pharmaceutical Industries Limited | 15.84 Billion USD | 72.353% |
| Zoetis Inc. | 8.54 Billion USD | 48.724% |